All In Biotech

Drug Trial Radar · NCT00811421

Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy

Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy

Last checked: Nov 19, 2026Latest source record: Mar 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 5,820 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,820

Actual

Start

Sep 2009

Primary completion

Dec 2012

Study completion Dec 2013

Sponsor

Lead sponsor
Hospital Clinic of BarcelonaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Barcelona Centre for International Health Research; Institute of Tropical Medicine, University of Tuebingen; Institut de Recherche pour le Developpement; Université d'Abomey-Calavi; Albert Schweitzer Hospital; Kenya Medical Research Institute; Ifakara Health Institute; Centro de Investigacao em Saude de Manhica; Vienna School of Clinical Research (VSCR), Austria.; Centers for Disease Control and Prevention; Malaria in Pregnancy Consortium
First posted
Dec 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study aims at comparing the safety, tolerability and efficacy of Mefloquine (MQ) to Sulfadoxine-Pyrimethamine (SP) as Interment Preventive Treatment in pregnancy (IPTp) for the prevention of malaria effects on the mother and her infant.

Conditions

  • Pregnancy
  • Malaria
  • HIV Infections

Interventions

  • Sulphadoxine-pyrimethamineDrug

    SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit

  • Mefloquine (full dose)Drug

    MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp

  • Mefloquine (split dose)Drug

    MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp

  • placeboDrug

    MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp

  • mefloquineDrug

    MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trial 1 (IPTp MQ vs IPTp SP): Low birth weight.Time frame: day 0, birth
  2. Trial 2 (CTX+IPTp MQ vs. CTX+IPTp placebo): Peripheral parasitaemia.Time frame: day 0, delivery

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Faculté des Sciences de la Santé (FSS), Université d'Abomey Calavi

    Allada, Benin

  • Medical Rsearch Unit (MRU), Albert Schweitzer Hospital

    Lambaréné, Gabon

  • Kenya Medical Research Institute (KEMRI)/ CDC

    Kisumu, Kenya

  • Centro de Investigaçao em Saúde da Manhiça (CISM)

    Manhiça, Maputo Province, Mozambique

  • Ifakara Health Institute (IHI)

    Dodoma, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.